Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Decitabine-induced CD38 upregulation augments daratumumab activity in xenograft T-ALL

ABSTRACT: This study investigates epigenetic regulation of CD38 in T-cell acute lymphoblastic leukemia (T-ALL) and the effect of decitabine (DEC) on CD38 promoter methylation and CD38 expression. Genome-wide DNA methylation profiling was performed in T-ALL cell lines treated with DEC or DMSO and in baseline T-ALL patient-derived xenograft (PDX) samples using the Illumina Infinium MethylationEPIC BeadChip v2.0.

ORGANISM(S): Homo sapiens

PROVIDER: GSE347263 | GEO | 2026/09/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Decitabine-induced CD38 upregulation augments daratumumab activity in xenograft T-ALL

Project description:Decitabine-induced CD38 upregulation augments daratumumab activity in xenograft T-ALL

| PRJNA1529224 | ENA

Whole methylome analysis of SEM cell lines

Project description:Genome-wide DNA methylation profiling of human B-ALL cell line SEM after 48 h incubation with DMSO (control), CX-4945 (Silmitasertib), Decitabine (DEC) or combined CX-4945 + DEC treatment. The Infinium MethylationEPIC BeadChip was used to obtain DNA methylation profiles across approximately 866,895 CpG islands.

2018-02-12 | GSE110454 | GEO

Enzymatic methylation sequencing of LOUCY and SUP-T1 cell lines after treatment with Decitabine (3 days) or GSK3685032 (3 and 7 days)

Project description:Decitabine (DEC) has a known DNA demethylating activity but also cause cytotoxicity through DNA damage. The two differing mechanisms of action confound studies investigating the effect of DNA demethylation in cancer treatment. The novel DNA methyltransferase 1 specific inhibitor GSK-3685032 causes loss of DNA methylation without DNA damage and offers the possibility to examine the molecular consequences of global loss of DNA methylation. EM-seq was used to evaluate the DNA demethylating effects of DEC and GSK-3685032 in LOUCY and SUP-T1 cells treated with 10 nM Decitabine for 3 days or 300 nM of GSK-3685032 for 3 and 7 days.

2024-10-13 | E-MTAB-14202 | biostudies-arrayexpress

Genome-wide DNA methylation maps of Decitabine and/or Cisplatin treated bladder cancer cells.

Project description:It is well established that low-dose Decitabine treatment can sustain long-term antitumor effects by targeting DNA methylation and altering gene expression32. We performed methylated DNA immunoprecipitation (MEDIP) followed by next-generation sequencing in 5637 cells. Daily Decitabine treatment with 100 nM for 72 hr (with or without 100ng/ml cisplatin treatment) reduced the methylation level at CpG-islands in the genome of 5637 cells . However, this low-dose DEC treatment did not cause a significant reduction of DNA methylation in non-CpG islands regions.Our study represents the first detailed analysis of DNA methylome generated by RNA-seq technology in bladder cancer cells treated with low-dose decitabine. This study help to reveal the direct target genes of decitabine in bladder cancer treatement.

2021-04-23 | GSE113537 | GEO

Targeting CD38 with Daratumumab in refractory Systemic Lupus Erythematosus

Project description:Single cell transcriptome and TCR sequencing of FACS-sorted memory T cells in one patient under treatment with the anti CD38-antibody Daratumumab. The patient received Daratumumab at days 0, 7, 14 and 21. Analyses were performed on day 0, 41 and 74.

2020-09-11 | GSE153765 | GEO

Epigenome analysis of MTHFD2 as a biomarker for decitabine response in MDA-MB-231 tumours

Project description:Genome-wide DNA methylation profiling of MDA-MB-231 tumours with or without MTHFD2 knockdown and decitabine treatment. The Illimuna Infinium MethylationEPIC DNA Beadchip v-1-0 B3 was used to obtain DNA methylation performed by The Centre for Applied Genomics in Toronto, Canada.

2024-11-01 | GSE267582 | GEO

Targeting CD38 with Daratumumab in refractory Systemic Lupus Erythematosus

Project description:Targeting CD38 with Daratumumab in refractory Systemic Lupus Erythematosus

| PRJNA643996 | ENA

SUM159 BrCa Decitabine Gene Expression

Project description:Dysregulation of DNA methylation is an established feature of breast cancers. DNA demethylating therapies like decitabine are proposed for the treatment of triple-negative breast cancers (TNBCs) and indicators of response need to be identified. For this purpose, we characterized the effects of decitabine in a panel of 10 breast cancer cell lines and observed a range of sensitivity to decitabine that was not subtype-specific. Knockdown of potential key effectors demonstrated the requirement of deoxycytidine kinase (DCK) for decitabine response in breast cancer cells. In treatment-naive breast tumors, DCK was higher in TNBCs, and DCK levels were sustained or increased post chemotherapy treatment. This suggests that limited DCK levels will not be a barrier to response in TNBC patients treated with decitabine as a second line treatment or in a clinical trial. Methylome analysis revealed that genome-wide, region-specific, tumor suppressor gene-specific methylation, and decitabine-induced demethylation did not predict response to decitabine. Gene set enrichment analysis (GSEA) of transcriptome data demonstrated that decitabine induced genes within apoptosis, cell cycle, stress, and immune pathways in decitabine treated cells. Induced genes included those characterized by the viral mimicry response; however knockdown of key effectors of the pathway did not affect decitabine sensitivity suggesting that breast cancer growth suppression by decitabine is independent of viral mimicry. Finally, taxol-resistant breast cancer cells expressing high levels of multidrug resistance transporter ABCB1 remained sensitive to decitabine, suggesting that the drug could be used as second-line treatment for chemoresistant patients. We used microarrays to determine genome-wide expression changes induced by DNA de-methylating agent decitabine in breast cancer cell lines

2020-06-01 | GSE133987 | GEO

Expression profile of PBMCs following decitabine treatment

Project description:The epigenetic regulation, for example, DNA methylation, controls the development and differentiation of both tumor cells and immunocytes. Treatment with DNA demethylating agent (such as decitabine) has shown a dramatic clinical benefit in hematological malignancies and solid tumors. However, the influence of epigenetic therapy on host immune system remains unclear. To investigate the effects of low-dose decitabine therapy on T cells, We collected whole blood samples from two solid tumor patients pre and post low-dose decitabine therapy, and detected the expression profiles of PBMCs.

2016-06-30 | E-GEOD-72686 | biostudies-arrayexpress

Genomics of decitabine responses

Project description:Global DNA methylation was analyzed in total bone marrow cells of AML/MDS patients undergoing decitabine treatment.

2016-04-30 | GSE80762 | GEO